Whalesbook
FDA Approval Sparks Stock Dip Amid Strong Financials
Lupin Pharmaceuticals announced Wednesday, May 13, 2026, that it received FDA approval for its Abbreviated New Drug Application (ANDA) for Famotidine Injection USP. This approval for 20 mg/2 mL (10 mg/mL) single-dose vials makes Lupin a supplier of a generic equivalent to Merck Sharp & Dohme Corp.'s Pepcid Injection. The drug is for intravenous use in hospitalized patients with pathological hypersecretory conditions or intractable ulcers, and as an alternative for those unable to take oral medication.
Famotidine Injection targets an estimated annual U.S. market of $8.7 million. While this is another step in Lupin's strategy to expand its complex generics and injectables portfolio, the market reaction was unexpectedly subdued. The stock closed down 1.36% on the BSE, despite these dual positive developments. This muted response suggests investors might be weighing the modest revenue potential of this approval against the company's overall performance or broader market trends. The company's U.S. business is projected to sustain over $1 billion in revenue, driven by biosimilars and its specialty portfolio.
Robust Q4 Earnings Show Strong Financial Growth
The pharmaceutical giant's financial results for the January-March quarter of FY26 showed a robust picture. Lupin nearly doubled its consolidated net profit year-on-year to ₹1,460 crore, a 97% increase. Revenue from operations surged 31.9% to ₹7,475 crore. This strong performance was primarily driven by exceptional results in its U.S. generics business and broad-based revenue growth across global markets.
For the full fiscal year 2026, consolidated net profit grew 62.5% to ₹5,333 crore, with revenue increasing 23.1% to ₹27,958 crore. The company's market capitalization stands around ₹1.01-1.09 trillion, and its trailing twelve months P/E ratio is in the mid-20s.
Industry Shift to Injectables and Competitive Landscape
Lupin's move into famotidine injectables follows a larger industry trend of drugmakers shifting from lower-margin oral generics to higher-margin injectables. The U.S. generic sterile injectable market is substantial and projected for significant growth. Estimates place its value at over $23 billion in 2026 and potentially reaching $38 billion to $48 billion by 2034, with compound annual growth rates between 7.95% and 11%.
Lupin's focus on complex generics and injectables is crucial for navigating pricing pressures in traditional oral generic segments. Key rivals in the U.S. generics and injectables space include Cipla, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Zydus Lifesciences. While Lupin holds a strong position in the U.S. generics market, ranking third by prescription volume, the famotidine injection faces competition from established players and adds to its existing portfolio of approved products.
Historically, Lupin's stock has shown muted reactions to regulatory approvals. In May 2025, shares traded flat to lower following U.S. FDA approvals for Raltegravir Tablets and Eslicarbazepine Acetate Tablets. This suggests that while regulatory wins are positive, their immediate stock impact can be limited, especially when market expectations are already high or when newer, more significant growth drivers are anticipated.
Challenges: Modest Market, Past Scrutiny, and Analyst Views
The estimated U.S. market size for Famotidine Injection, around $8.7 million, presents a modest revenue opportunity. While it contributes to Lupin's expanding injectable portfolio, it's unlikely to be a significant revenue driver on its own. Investors might be looking for larger market opportunities or more substantial contributions from new product launches.
Furthermore, Lupin has faced regulatory scrutiny. In September 2025, its share price declined after the U.S. FDA issued adverse observations following an inspection of its Nagpur manufacturing unit. While Lupin stated it would address these observations, such past issues can concern investors, especially when manufacturing is key to supply, as it is for this injection.
Investor caution is also fueled by reports of some analysts downgrading Lupin shares to 'Hold' despite strong earnings. This suggests they believe current valuations already price in future growth, or that concerns over margin pressures and competition are impacting sentiment. The company's strategy to transition its portfolio towards higher-complexity assets like injectables is a sound long-term approach, but the immediate impact of individual approvals like famotidine injection might not be enough to overcome these broader market perceptions.
Strategic Focus on Complex Generics Pipeline
Lupin's direction towards complex generics and injectables is critical for sustained growth and margin expansion in a competitive pharmaceutical environment. The company's ability to consistently secure regulatory approvals for these higher-value products will be key to re-rating its valuation. Future performance will likely hinge on the successful commercialization of its pipeline and its capacity to navigate ongoing regulatory compliance and competitive challenges in major markets like the U.S.